36 results about "Heart Hypertrophy" patented technology

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.

The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2, NF-AT3, calcineurin, MCIP, and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of many of these factors or the pathways mediated by these factors has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between these factors and the pathways they mediate through a family of non-voltage gated channels called TRP channels. The present invention further demonstrates that inhibitors of TRP channels can inhibit or treat heart failure and cardiac hypertrophy.

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

Compositions and methods are disclosed for stimulating or inhibiting angiogeniesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Methods and compositions are provided for the diagnosis and treatment of heart diseases relating to cardiac hypertrophy, and for the regulation of proliferation and differentiation of cardiomyocyte progenitors in vitro. The detection of expression of components of the BAF complex, including, without limitation, detection of expression of Brg1, provides useful methods for early detection, diagnosis, staging, and monitoring of conditions leading to hypertrophy and enlargement of the heart. Manipulation of Brg1 activity provides for therapeutic intervention in the development of cardiac hypertrophy, where methods of decreasing Brg1 activity, e.g. through inhibition of binding, decreasing expression, and the like, reduces cardiac hypertrophy.

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

This present invention discloses an isolated peptide which amino acid sequence is SEQ ID NO.:1. The isolated peptide can inhibit the expressions of signal transduction proteins related to the heart hypertrophy pathway, apoptosis of myocardial cells related proteins, and cardiac fibrosis related proteins to have effects of preventing such as apoptosis of myocardial cells, cardiac fibrosis, heart hypertrophy, cardiac inflammation or other heart diseases. Therefore, the peptide disclosed in this present invention can be an active ingredient of pharmaceutical composition to have effects for preventing or treating cardiovascular disease.

The invention relates to a traditional Chinese medicine, in particular to a Yu'naoxin medicament, having the major functions of treating blood reflux caused by cardiac valvular inadequacy, and cardiac hypertrophy, chest distress and short breath, dysphoria, irritability, cerebral circulation insufficiency, cardiovascular stenosis and cerebral infarction, caused by cardiac blood reflux. The Yu'naoxin medicament is made from, by equal weight, Chinese angelica root, rhizome of Szechuan lovage, root of red-rooted salvia, leech, earthworm, turmeric root-tuber, safflower, uncaria stem with hooks, polygala root, jujube kernel, poria with hostwood, rhizome of oriental water plantain, red peony root, root of Dhahran angelica, kudzuvine root, prepared rhizome of rehmannia, white atractylodes rhizome, licorice root, silktree Albizzia flower, peach kernel, Chinese thorowax root, and Szechwan chinaberry fruit. 399 clinical cases show that total effective rate is higher than 89%; the Yu'naoxin medicament has significant effects and is convenient to popularize.

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and/or cardiac fibrosis.

The present invention relates to a pharmaceutical composition for treating cardiac hypertrophy, comprising at least a stem cell and a pharmaceutically acceptable vehicle, wherein the stem cell is prepared by a pretreatment reaction of reacting with an n-butylidenephthalide (BP). The pharmaceutical composition of the present invention can be administered into a body of a hypertensive patient by remote intramuscular injection, so as to reduce superoxide content in the myocardium, increase STAT3 activity, and increase the content of M2 macrophages that promote inflammation resolution, and further effectively treat the symptoms of cardiac hypertrophy caused by hypertension.

A computer-implemented method for facilitating opportunistic screening for cardiomegaly includes obtaining a set of computed tomography (CT) images. The set of CT images captures at least a portion of a heart of a patient, and the set of CT images is captured for a purpose independent of assessing cardiomegaly. The method further includes using the set of CT images as an input to an artificial intelligence (AI) module configured to determine a heart measurement based on CT image set input. The method also includes obtaining heart measurement output generated by the AI module and, based on the heart measurement output, classifying the patient into one of a plurality of risk levels for cardiomegaly. The classification is operable to trigger additional action based on the corresponding risk level for the patient.

The present invention refers to human microRNA hsa-miR-665 for the treatment or prevention of heart diseases associated with cardiac hypertrophy and consequent pathological remodeling of the heart, in particular for preventing and/or treating heart failure (HF). Vectors and pharmaceutical compositions comprising said miRNA for the disclosed uses are also within the scope of the present invention.

The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

The present invention relates to a composition for screening antihypertensive drugs, which contains a mammalian TCTP gene or a protein expressed therefrom, as well as a method for screening antihypertensive drugs using the composition. TCTP contained in the inventive composition acts as a cytoplasmic inhibitor of the Na/K APTase pump, thus causing hypertension and heart hypertrophy. Therefore, the inventive composition and the screening method using the same will be useful for the investigation and development of antihypertensive drugs. Furthermore, the inventive TCTP-overexpressing transgenic mice shows hypertension or heart hypertrophy as a phenotype. Thus, the inventive transgenic mice will be useful in screening test substances developed for the treatment and improvement of hypertension and heart hypertrophy, by administering the test substance to the transgenic mice and observing the extent of treatment and improvement.

The invention provides a cardiothoracic ratio calculation method and a cardiac hypertrophy distinguishing method and device.The cardiothoracic ratio calculation method comprises the steps that a cardiothoracic region image of a target patient is obtained; extracting a heart outer contour and left and right pulmonary parenchyma area outer contours from the cardiothoracic area image; based on the heart outer contour and the left and right lung parenchyma area outer contours, respectively calculating the longitudinal distance of the heart area outer contour and the longitudinal distance of the left and right lung area outer contours; based on the heart area outer contour longitudinal distance and the left and right lung area outer contour longitudinal distance, a cardiothoracic ratio result is obtained through calculation. The heart and left and right lung area outer contour longitudinal distances are respectively calculated by using the cardiothoracic area image of the patient, and the cardiothoracic ratio result is calculated according to the heart and left and right lung area outer contour longitudinal distances, so that the manual measurement step in manual cardiothoracic ratio measurement is greatly reduced; the data of the heart area and the left and right lung areas are acquired and calculated by adopting an image recognition processing mode, so that the accuracy of a cardiothoracic ratio result is ensured.